Tumor necrosis factor-␣ (TNF-␣) is being used as an antineoplastic agent in treatment regimens of patients with locally advanced solid tumors, but TNF-␣ alone is only marginally active. In clinical use, it is usually combined with other chemical agents to increase its tumor response rate. Our previous studies reported that LYG-202 (5-hydroxy-8-methoxy-7-(4-(4-methylpiperazin-1-yl)butoxy)-2-phenyl-4H-chromen-4-one), a synthesized flavonoid with a piperazine substitution, has antiproliferative, antiangiogenic, and proapoptotic activities in multiple cancer cell lines. Here we evaluated the antineoplastic effect of TNF-␣ and analyzed the mechanism underlying its combination with LYG-202. Our results indicated that LYG-202 significantly increased the cytostatic and proapoptotic activity of TNF-␣ in HepG2 cells and heightened the protein level of apoptosis-related genes including caspase-3, caspase-8/9, cleaved poly(ADPribose) polymerase, and Bid. The fact that LYG-202 had a fitness score similar to that of the casein kinase 2 (CK2) inhibitor naphthyridine-8-carboxylate (CX-4945) implied to us that it may serve as a potential candidate for CK2 inhibitor, and the kinase activity assay suggested that LYG-202 significantly inhibited CK2 activity. Moreover, the electrophoretic mobility shift assay and luciferase assay showed that LYG-202 blocked the TNF-␣-induced nuclear factor-B (NF-B) survival signaling pathway primarily by inactivating protein kinase CK2. In murine xenograft models, we also found that LYG-202 enhanced TNF-␣ antineoplastic activity and inhibited CK2 activity and NF-B-regulated antiapoptotic gene expression. All these results showed that LYG-202 enhanced TNF-␣-induced apoptosis by attenuating the CK2-dependent NF-B pathway and probably is a promising agent in combination with TNF-␣.
Introduction
Tumor necrosis factor-␣ (TNF-␣) is a multifunctional cytokine playing roles in apoptosis, cell survival, inflammation, and immunity by triggering distinct signals (Wallach, 1997; Pfeffer, 2003; Balkwill, 2009) . In several preclinical models and clinical trials, it exerts a direct cytotoxic effect to induce tumor regression and now serves as an antineoplastic agent for patients with locally advanced solid tumors (Egberts et al., 2008; Pilati et al., 2008) . However, TNF-␣ alone shows only marginal activity, even with administration at high doses through local drug delivery systems. To increase ma- lignant cell sensitivity to TNF-␣, it is combined with conventional antineoplastic agents (e.g., melphalan, paclitaxel, and actinomycin D) in clinical use (Manusama et al., 1996; de Wilt et al., 2000; Seynhaeve et al., 2002) .
The majority of TNF-␣ biological activity is initiated via tumor necrosis factor receptor-1 (TNFR-1). TNF-␣ homotrimer binding to the extracellular domain of TNFR-1 induces TNFR-1 trimerization and releases the inhibitory protein silencer of death domains from TNFR-1 intracellular death domain and then recruits the adaptors including TNFR-associated death domain protein, Fas associated protein with death domain and caspase-8 and modulates caspase-9 and caspase-3. The activated caspase-8 and caspase-3 can induce Bid and PARP cleavage, respectively, and switch on cell apoptosis programs (Perez and White, 2000; Los et al., 2002) . On the contrary, the bond also activates IB kinase (IKK) and phosphorylates IB, leading to its subsequent ubiquitination and proteasomal degradation, thereby allowing activated nuclear factor-B (NF-B) to translocate into the nucleus where it binds to specific sequences of DNA and activates the expression of some antiapoptosis genes (Aggarwal, 2003; Sung et al., 2008) , and the NF-B signal is considered to be the major blocker in TNF-␣-induced apoptosis. Thus, researchers explored agents that interfere with NF-B survival pathway to reverse the resistance of both solid tumors and hematological malignancies to TNF-␣ (Uzzo et al., 2002; Braun et al., 2006) and improve the efficacy of apoptosis-inducing cancer therapies (Orlowski and Baldwin, 2002; Mocellin et al., 2005) .
Flavonoids refer to a series of naturally occurring, lowmolecular-weight plant products exhibiting a variety of biological activities such as antibacterial, antiviral, anti-inflammatory, antiallergic, and vasodilatory activities (Middleton et al., 2000; Nakamura et al., 2003; Suk et al., 2003) . LYG-202 (5-hydroxy-8-methoxy-7-(4-(4-methylpiperazin-1-yl)butoxy)-2-phenyl-4H-chromen-4-one), a known synthesized flavonoid with a piperazine substitution (Fig. 1A) , showed stronger antitumor effects than its parent compound (Zeng et al., 2009) . Our previous studies showed that it has proapoptotic, antiproliferative, and antiangiogenic activities in vivo and in vitro (Zeng et al., 2009; Chen et al., 2010a,b; Liu et al., 2011) . In the study, we investigated the effect of LYG-202 on NF-B signaling and apoptosis in response to TNF-␣. These results demonstrated that LYG-202 could augment TNF-␣-induced apoptosis by blocking the NF-B pathway. However, the exact molecular mechanism remains to be fully elucidated. Therefore, the inverse-docking approach was performed to screen potential protein targets of LYG-202 on the NF-B pathway [e.g., casein kinase 2 (CK2), MEKK1, MEKK3, transforming growth factor ␤-activated kinase 1, and protein kinase C].
CK2, a highly conserved and ubiquitous serine/threonine protein kinase that participates in the transduction of signals that promote cell growth and survival, plays a critical role in various steps of NF-B signal activation induced by TNF-␣ (Litchfield, 2003) . First, it activates IKK␤ kinase and phosphorylates IB␣ on Ser32/Ser36 and COOH-terminal proline-glutamic acid-serine-threonine residues (Schoonbroodt et al., 2000) and then phosphorylates the Rel A on Ser529, and this has a direct effect on the amplitude of transactivation (Wang et al., 2008) . Hence, agents that can suppress CK2-induced NF-B activation and enhance TNF-␣-induced cell apoptosis could significantly improve the antitumor activity of TNF-␣ (Siddiqui-Jain et al., 2010) .
In the present study, we evaluated the antineoplastic effect of TNF-␣ with or without LYG-202 in human hepatocellular carcinoma HepG2 cells, which are not sensitive to TNF-␣ (Sugimoto et al., 1999; Kusaba et al., 2007) . Our results indicated that LYG-202 weakened CK2 activity and enhanced TNF-␣-induced apoptosis by attenuating NF-B signaling pathway in vitro and in vivo.
Materials and Methods
Materials. LYG-202 was synthesized by Dr. Zhiyu Li (China Pharmaceutical University, Nanjing, China), dissolved in dimethyl sulfoxide as a stock solution (10 mM) and stored at Ϫ20°C, and freshly diluted with RPMI 1640 medium (Invitrogen, Carlsbad, CA) to the final concentration. The control groups were always treated with dimethyl sulfoxide (0.1%, v/v). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Fluka Chemical Corp. (Ronkonkoma, NY) and dissolved in 0.01 M PBS. Recombinant human TNF-␣ was purchased from PeproTech (Rocky Hills, NJ), and recombinant mouse TNF-␣ was purchased from ProSpec-Tany TechnoGene Ltd. (Ness Ziona, Israel). Z-VAD-FMK (a caspase inhibitor) was purchased from Beyotime Institute of Biotechnology (Nantong, China). 5-(3-Chlorophenylamino benzo[c][2,6]naphthyridine-8-carboxylate (CX-4945) was obtained from Biochempartner Co. Ltd. (Shanghai, China). Primary antibodies of caspase-3, caspase-8, caspase-9, Bid, green fluorescent protein, Survivin, XIAP, c-Myc, MMP-9, p65, IB␣, phospho-IB␣, and ␤-actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against Bcl-2, Bcl-xL, and histones were obtained from Bioworld (St. Louis Park, MN). Antibodies against PARP, COX-2, and cyclin D1 were purchased from Cell Signaling Technology (Beverly, MA). Anti-CK2␣/␣Ј antibody was purchased from BD Biosciences (San Jose, CA). The plasmids of CK2␣ and CK2␤ were a kind gift from Dr. Stefania Sarno (University of Padova, Padova, Italy). CK2␣ siRNA was obtained from Santa Cruz Biotechnology, Inc.
Cell Lines and Cell Culture. The human hepatoma HepG2, SMMC-7721, and BEL-7402 cell lines, the mouse hepatoma H 22 cell line, the liver L02 cell line, and the colon carcinoma HCT-116 cell line were originally obtained from the Cell Bank of Shanghai Institute of Cell Biology. HepG2 cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated calf serum (Sijiqing). SMMC-7721, BEL-7402, and L02 cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Sijiqing, Hangzhou, China). HCT-116 cells were cultured in McCoy's 5A supplemented with 10% heat-inactivated fetal bovine serum. All in the presence of TNF-␣ at a nongrowth inhibitory dose (50 ng/ml) (right). Cell viability was analyzed by the MTT method. E and F, potentiation of TNF-␣-induced cell growth inhibition in SMMC-7721 and BEL-7402 cells. Cell growth was analyzed by the MTT method. G, treatment effect of LYG-202 combined with TNF-␣ on cell proliferation in different hepatocellular carcinoma cell lines. The cells were pretreated with LYG-202 for 6 h and then incubated with TNF-␣ for 18 h. Cell growth was evaluated by the MTT method. H, LYG-202 enhances TNF-␣-induced apoptosis. The cells were pretreated with 2 M LYG-202 for 6 h and then incubated with 50 ng/ml TNF-␣ for 18 h. The morphology of HepG2 cells was observed under an inverted light microscope (400ϫ), stained with DAPI reagent, and then analyzed under a fluorescence microscope (400ϫ). I, cells pretreated with 2 M LYG-202 for 6 h and then incubated with 50 ng/ml TNF-␣ for 18 h were examined by annexin V-PI double-staining assay. The y-axis shows the PI-labeled population and the x-axis shows FITC-labeled annexin V-positive cells. J, apoptotic rate of HepG2 cells caused by LYG-202, TNF-␣, and their combination treatment. Values are means Ϯ S.D. for at least three independent experiments performed in triplicate ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01 compared with vehicle control). media were also supplemented with 100 U/ml penicillin (Beyotime Institute of Biotechnology) and 100 g/ml streptomycin (Beyotime Institute of Biotechnology) and maintained in a humidified atmosphere of 95% air/5% CO 2 at 37°C.
Animals. Male Kunming mice with body weight ranging from 18 to 22 g were provided by the animal facility at China Pharmaceutical University [No. SCXK (Su) 2002-0011] . Animals were maintained in a pathogen-free environment (23 Ϯ 2°C; 55 Ϯ 5% humidity) on a 12-h light/dark cycle with food and water supplied ad libitum throughout the experimental period.
Cell Viability Assay. Cells were plated at a density of 10 5 cells/ml per well in 96-well plates. After overnight growth, cells were exposed to medium containing LYG-202 for 6 h and then were treated with or without 50 ng/ml TNF-␣ for another 18 h at 37°C. Then cell viability was determined with the MTT method according to the previous description (Chen et al., 2010a) . Combined Effect Evaluation. Drug interaction between LYG-202 and TNF-␣ was assessed at a fixed concentration ratio of 1:1. The combination index (CI) was calculated as follows:
where (D X ) 1 and (D X ) 2 are the doses for LYG-202 and TNF-␣ in a combination that inhibits 50% cell growth, and (D) 1 and (D) 2 are the doses for each drug alone that inhibit 50% cell growth. CI Ͻ1, CI ϭ 1, and CI Ͼ1 indicate synergistic, additive, and antagonistic effects, respectively (Chou, 2006) . Data analysis was performed by CalcuSyn software (Biosoft, Oxford, UK).
Cell Morphology. HepG2 cells were seeded at 5 ϫ 10 5 cells/well in six-well plates and grown for 24 h to attach themselves to the surface of the plates completely. In brief, cells were incubated with 2 M LYG-202 for 6 h and then treated with or without 50 ng/ml TNF-␣ for another 18 h at 37°C, and a picture of live cells was taken under the inverted light microscope. In addition, their nuclei were photographed under a fluorescent microscope (IX51; Olympus, Tokyo, Japan) with a peak excitation wavelength of 340 nm after they were stained with DAPI as described previously (Zhang et al., 2010) .
Apoptosis Assessment. The apoptosis induced by TNF-␣ alone or with LYG-202 was detected by an annexin V-FITC apoptosis detection kit (BioVision, Milpitas, CA) according to the manufacturer's protocol. In brief, cells were pretreated with 2 M LYG-202 for 6 h and treated with 50 ng/ml TNF-␣ for 18 h. Then the cells were collected, resuspended in binding buffer (pH 7.5, 10 mM HEPES, 2.5 mM CaCl 2 , and 140 mM NaCl), and incubated with annexin V-FITC and then with PI for 10 min in the dark at room temperature. Cells were analyzed by flow cytometry (FACSCalibur; BD, Franklin Lakes, NJ) and a computer station running CellQuest software (BD).
Western Blot Analysis. HepG2 cells were incubated with 2 M LYG-202 for 6 h and then were treated with or without 50 ng/ml TNF-␣ for another 18 h at 37°C and collected. Western blot analysis for proteins was performed according to our previous methods (Chen et al., 2010b) .
Electrophoretic Mobility Shift Assay. To assess the effect of LYG-202 on TNF-␣-induced NF-B activation, an electrophoretic mobility shift assay (EMSA) was performed with a chemiluminescent EMSA kit (Beyotime Institute of Biotechnology) following the manufacturer's protocol. In brief, nuclear extracts (5 g/sample) were incubated with biotin-labeled oligonucleotides, 5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј and 3Ј-TCA ACT CCC CTG AAA GGG TCC G-5Ј (boldface indicates NF-B binding sites) in reaction buffers for 30 min at room temperature. The DNA-protein complex was separated from free oligonucleotide on 6% native polyacrylamide gels. The gels were visualized with a Bio-Rad infrared system and quantitated using Image Lab software (Bio-Rad Laboratories, Hercules, CA).
Cell Transfection and Luciferase Reporter Assay. The effect of LYG-202 on NF-B-dependent reporter gene transcription induced by TNF-␣ was analyzed by luciferase reporter gene assays. HepG2 cells (5 ϫ 10 5 cells/well) were plated in six-well plates and transfected transiently with the pNF-B-luc plasmid (Beyotime Institute of Biotechnology) containing four NF-B binding motifs (GGGAATTTCC) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instruction. The pCDNA3.2 plasmid was added to make the total amount of DNA equal (4 g/well in a six-well plate), and green fluorescent protein served as a normalization control. Then the cells were treated for 6 h with LYG-202 and stimulated with TNF-␣ (50 ng/ml) for another 18 h. Luciferase assays were performed with the Luciferase Reporter Gene Assay Kit (Promega, Madison, WI) and detected using Luminoskan Ascent (Thermo Fisher Scientific, Waltham, MA). Chromatin Immunoprecipitation Assay. The CHIP assay was performed generally following the recommendations described previously with some modifications. HepG2 cells were incubated with 2 M LYG-202 for 6 h and then treated with 50 ng/ml TNF-␣ for the indicated time. Cells were then cross-linked with formaldehyde, quenched with glycine, sonicated on ice, and centrifuged at 4°C. Mixtures were incubated with anti-p65 or preimmune IgG with rotation at 4°C overnight and then incubated with protein AϩG agarose at 4°C for 6 h. Finally, immune complexes were captured by protein AϩG agarose and eluted with elution buffer (1% SDS and 0.1 M NaHCO 3 ) at 37°C for 30 min. Cross-linking was reversed at 65°C for 4 h in a high salt buffer (0.2 M NaCl, 50 mM Tris, pH 6.5, 10 mM EDTA, and 0.2 mg/ml proteinase K). Extracted and dissolved immunoprecipitated DNA was quantified by real-time PCR with primers encompassing the NF-B binding sites. Primers for COX-2 promoter quantification were 5Ј-TCT GGC GGA AAC CTG TGC GCT GG-3Ј and 5Ј-AAA TTG CGT AAG CCC GGT GGG-3Ј (forward and reverse, respectively) and for MMP-9 promoter quantification were 5Ј-CAG TGG AAT TCC CCA GCC TTG CCT-3Ј and 5Ј-CCA CAC TCC AGG CTC TGT CCT C-3Ј. An equal volume of nonprecipitated (input) genomic DNA was used to correct for the differences in PCR amplification efficiencies and amounts of DNA. The PCR analyses were performed with a real-time PCR kit (TaKaRa Biotechnology Co. Ltd., Dalian, China).
Immunocytochemical Localization of NF-B/p65 Subunit. The effect of LYG-202 on the nuclear translocation of p65 was examined by immunocytochemical analysis as described previously. In brief, cells were pretreated with 2 M LYG-202 for 6 h after being seeded on a gelatin-coated glass, after stimulation with or without 50 ng/ml TNF-␣ for 30 min, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. After being washed with PBS, the fixed cells were blocked with 3% bovine serum albumin for 1 h and then incubated with rabbit polyclonal anti-p65 antibody (1:50) overnight at 4°C, washed with PBS and incubated with anti-rabbit IgG-FITC (1:100) for 1 h, and counterstained for nuclei with the fluorochrome dye DAPI (Santa Cruz Biotechnology, Inc.). Stained slides were observed under a fluorescence microscope (Olympus) with a peak excitation wavelength of 340 nm.
IKK␤ Activity Assay. The effect of LYG-202 on IKK␤ activity was determined using the HTScan IKK␤ kinase assay kit (Cell Signaling Technology) as described previously (Sun et al., 2010) .
Molecular Docking. We used our protein-ligand docking software package GOLD to dock LYG-202 into many potential drug targets that could activate IKK␤ activity (Hayden and Ghosh, 2004; Schmid and Birbach, 2008) . Molecular docking was performed following the method of Sun et al. (2010) . We then ranked each protein according to the GOLD fitness score. Inhibitors of the top targeted protein were considered to have effects on TNF-␣-induced apoptosis similar to LYG-202, which could be detected in the biological test. Previous studies showed that the binding site was defined by analyzing the protein-ligand interactions of cocrystal structures that were deposited in PDB (http://www.rcsb.org/pdb). Molecular interactions were observed using Discovery Studio (Accelrys, San Diego, CA). In the study, LYG-202 was detected for its interaction with major binding sites of selected proteins.
CK2 Activity Assay. CK2 activity after treatment with TNF-␣ alone or in combination with LYG-202 was detected with the CK2
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at ASPET Journals on June 26, 2017 molpharm.aspetjournals.org assay kit (MBL International, Woburn, MA) according to the manufacturer's instruction (Sun et al., 2010) . Down-Regulation of CK2 by siRNA. HepG2 cells were plated at 5 ϫ 10 5 cells/well in six-well plates and allowed to adhere for 24 h. siRNA transfections were performed according to the manufacturer's instructions for Lipofectamine 2000 reagent. After that, HepG2 cells preincubated with 2 M LYG-202 for 6 h and then treated with or without 50 ng/ml TNF-␣ for another 18 h at 37°C were recovered and used for appropriate determinations.
Real-Time PCR Analysis. Total RNA was extracted using TriPure Isolation Reagent (Roche Diagnostics, Mannheim, Germany) and then were amplified by PCRs. The primer sets used in the PCR amplification were as follows: for CK2␣, forward 5Ј-TCA CAG CAG CAT GGG AAT TAT GCA C-3Ј and reverse 5Ј-AGC AAC TCG GAC ATT ATA TTC TTG G-3Ј. The relative expression of CK2␣ was analyzed using quantitative RT-PCR with glyceraldehyde-3-phosphate dehydrogenase as an internal control as described previously (Lu et al., 2012) .
Murine Xenograft Tumor Assay. Murine hepatoma 22 (H 22 ) cells were diluted with ice-cold 0.9% saline and inoculated subcutaneously at the right axilla of mice (5 ϫ 10 6 viable cells/ml) (Wang et al., 2008; Zhao et al., 2010) . Twenty-four hours after inoculation, mice were divided randomly into 11 groups (with 10 mice/group): saline tumor control group; TNF-␣ 1.5 g/day group; LYG-202 750, 500, 250, and 125 mg/kg; LYG-202 750, 500, 250, and 125 mg/kg ϩ TNF-␣ combination group; and 10-hydroxycamptothecin 30 mg/kg group. Mice were administered LYG-202 or 10-hydroxycamptothecin orally and TNF-␣ by subcutaneous injections, which were given once every 2 days. From the 3rd day after treatment, the tumors were measured continuously. Tumor volume (TV) was calculated using the formula
where d and D are the shortest and the longest diameter, respectively. At the 7th day after treatment, the mice were sacrificed, and tumors were ablated carefully and weighed after any remaining blood was washed off with PBS. The tumor inhibitory ratio was calculated by the formula
where W Treated and W Control are the average tumor weights of the treated and control mice, respectively. This study was approved in the SPF animal laboratory of China Pharmaceutical University.
The coefficient of drug interaction (CDI) was used to analyze effects of drug combinations (Cao and Zhen, 1989) . CDI is calculated as follows:
According to the tumor weight of each group, AB is the ratio of the combination groups to control group, and A or B is the ratio of the single agent group to the control group. When CDI ϭ Ͻ1, synergism is indicated. When CDI ϭ 1, summation is indicated. When CDI ϭ Ͼ1, antagonism is indicated. CDI ϭ Ͻ0.75 indicates that the drugs are significantly synergistic.
Histology. Hepatoma tumors were fixed in 10% formalin and processed routinely for paraffin embedding. Tissue sections were prepared with a microtome and placed on glass slides. A TUNEL assay was performed to detect apoptotic cells using a TUNEL detection kit (KeyGEN, Nanjing, China) according to the manufacturer's instructions.
Statistical Analyses. All quantitative data are presented as the mean Ϯ S.D. from at least three samples per data point. Statistical analyses were performed using an unpaired, two-tailed Student's t test. All comparisons are made relative to untreated controls, and significance of difference is indicated as ‫,ء‬ P Ͻ 0.05 and ‫,ءء‬ P Ͻ 0.01.
Results
LYG-202
Enhances TNF-␣-Induced Growth Inhibition and Apoptosis. The inhibitory effects of LYG-202 and TNF-␣ on cell viability in HepG2 cells were assessed after incubation with increasing concentrations of LYG-202 and TNF-␣ for 24 h. Results indicated that LYG-202 and TNF-␣ showed an inhibitory effect in a concentration-dependent manner (Fig. 1B) , and the IC 50 of LYG-202 and TNF-␣ was 262.02 Ϯ 12.52 ng/ml and 5.98 Ϯ 0.65 M, respectively. To investigate the inhibitory effect of the combination treatment, cells were exposed to LYG-202 for 6 h and then incubated with TNF-␣ for 18 h at a fixed ratio (LYG-202 IC 50 / TNF-␣ IC 50 ratios were 1:1) (Chou, 2006) . Data in Fig. 1C show that the CI values were Ͻ1 when the values of fraction affects (Fa) were smaller than 0.409 (at the point at which the concentration of LYG-202 and TNF-␣ was approximately 2.05 M and 88.91 ng/ml, respectively), which indicated that the combination of TNF-␣ and LYG-202 exerted a synergistic inhibitory effect on cell proliferation in HepG2 cells at concentrations smaller than the threshold values (drug concentrations when CI ϭ 1).
To further determine the effect of LYG-202 on TNF-␣-induced growth inhibition of HepG2 cells, we treated HepG2 cells with different concentrations of TNF-␣ or LYG-202 alone or in combination. Our results indicated that treatment with TNF-␣ alone had little effect on the growth of HepG2, but there was a moderate inhibitory effect with LYG-202 alone, and in the presence of a moderate inhibitory dose of TNF-␣ (50 ng/ml) or LYG-202 (2 M), the combination was highly effective on HepG2 cell growth (Fig. 1D) . Similar effects were observed in SMMC-7721 (Fig. 1E ) and BEL-7402 cells (Fig. 1F) .
The cell viability with TNF-␣ alone (50 ng/ml), LYG-202 alone (2 M), and the combination was 98.3, 95.6, and 65.5%, respectively, in HepG2 cells. These results suggested the significant synergy of TNF-␣ and LYG-202 on the inhibition of HepG2 cell proliferation. Similar results were also found for the combination of LYG-202 with TNF-␣ in different hepatocellular carcinoma cell lines (Fig. 1G) .
Then we analyzed the effect of LYG-202 on TNF-␣-induced apoptosis, which is one of the major ways for cell death (Bosman et al., 1996) , with DAPI and annexin V-PI double staining. Results indicated that the live cells were obviously decreased (Fig. 1H, top row) , and the number of cells in which the chromatins condensed increased (Fig. 1H, bottom row) . Moreover, annexin V-PI double-staining analysis indicated that LYG-202 potentiated TNF-␣-induced early apoptosis from 0.72 to 19.43% and late apoptosis strikingly from 2.01 to 40.62% (Fig. 1, I and J), suggesting a synergistic effect of LYG-202 with TNF-␣ in inducing cell apoptosis.
LYG-202 Potentiated TNF-␣-Induced Caspase Activation and Bid and PARP Cleavage in HepG2 Cells. To understand the role of caspases in TNF-␣-mediated apoptosis with or without LYG-202, Western blotting was performed. We found that TNF-␣ alone had a minimal effect on the protein level of cleavage of caspase-8 and -3/9 and their activated form, and no effect on procaspase-8 and -3/9. In the presence of LYG-202, however, the cleaved products markedly accumulated, whereas the level of procaspase-8 and -3/9 decreased in a time-dependent manner ( Fig. 2A) .
Bid is a specific proximal substrate of caspase-8, and cleavage of both is a feature of TNF-␣ lethality (Li et al., 1998; Perez and White, 2000) . The proteolytic cleavage of PARP, a substrate of caspase-3, has been considered to be a hallmark of apoptosis (Los et al., 2002) . Therefore, the cleavages of Bid and PARP were also tested. Western blot analysis suggested that neither TNF-␣ nor LYG-202 alone had an effect on Bid and PARP cleavage, but together they were very effective in inducing cleavages of Bid and PARP ( Fig. 2A) . These results indicated that LYG-202 can facilitate the activation of caspase and cleavages of Bid and PARP in the TNF-␣-induced apoptotic pathway.
LYG-202 Suppressed the Expression of NF-B-Regulated Gene Products in HepG2 Cells. We know that TNF-␣ triggers both the caspase-protease pathway and the NF-B pathway, and the balance of these two pathways is critical for the ultimate fate of a cell: death or survival (Brown et al., 2010) . These findings prompted us to determine whether LYG-202 could enhance TNF-␣-induced apoptosis by attenuating the NF-B pathway.
To examine the effect of LYG-202 on the NF-B pathway, we analyzed the expression of its downstream genes involved in antiapoptosis (Survivin, XIAP, Bcl-2, and Bcl-xL), proliferation (cyclin D1, COX-2, and c-Myc), and invasion (MMP-9). As shown in Fig. 2B , in the absence of LYG-202, TNF-␣ induced the expression of survival and invasion genes including Survivin, XIAP, Bcl-2, COX-2, and MMP-9 in a timedependent manner. Of interest, the level of cyclin D1 and c-Myc increased for the first 12 h but decreased at 24 h, whereas that of Bcl-xL showed little change. However, in the presence of LYG-202, the increase in these gene expressions was weakened and even reversed. Pretreatment with Z-VAD-FMK, a caspase inhibitor, barely blocked the down-regulation of NF-B-mediated gene expression, suggesting that the down-regulation of various target proteins was not caspasedependent and may be upstream of the apoptotic pathway. 
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at ASPET Journals on June 26, 2017 molpharm.aspetjournals.org plex in nuclear extracts was evaluated by EMSA. As shown in Fig. 3 , LYG-202 alone had a minimal effect on NF-B activation at different doses and time courses (Fig. 3A , left column), whereas it significantly inhibited TNF-␣-induced NF-B activation in dose-and time-dependent manners (Fig.  3A, right column) .
LYG-202 Repressed TNF-␣-Activated NF-B-Dependent Gene Transcription. To determine the effect of LYG-202 on NF-B-dependent gene transcription directly, a p65-luciferase reporter gene assay was performed. Results indicated that LYG-202 inhibited TNF-␣-induced p65 reporter gene activity in a dose-dependent manner (Fig. 3B) .
To further confirm these data, we performed a CHIP assay to test the activity of NF-B binding to promoters of COX-2 and MMP-9, two NF-B target genes. Results showed that TNF-␣ induced this activity in a time-dependent manner, whereas LYG-202 abolished it (Fig. 3C) .
These findings suggested that LYG-202 strongly inhibited TNF-␣-induced NF-B-dependent gene transcription by interfering with the binding of NF-B to its target gene promoters in HepG2 cells.
LYG-202
Inhibited TNF-␣-Induced Nuclear Translocation of p65. The nucleus localization of p65, a subunit of the NF-B complex, is essential for the transcriptional activity of NF-B (Mocellin et al., 2005) , so nuclear and cytoplasmic extracts were obtained to examine the nuclear translocation of p65. Results showed that TNF-␣-induced nuclear translocation of p65 was detected in 15 min and lasted for more than 1 h (Fig. 4A, left column) , whereas it was inhibited by LYG-202 (Fig. 4A, right column) . Similar data were also observed in the immunofluorescence assay (Fig. 4B) . These results suggested that LYG-202 interferes with TNF-␣-induced p65 (a subunit of NF-B) nuclear translocation in HepG2 cells.
LYG-202 Inhibited TNF-␣-Mediated IB␣ Phosphorylation and Degradation and IKK␤ Activity. NF-B activates the transcription of target genes by binding with a consensus sequence in the nucleus, and the translocation of NF-B to the nucleus is preceded by the phosphorylation, ubiquitination, and proteolytic degradation of IB (Karin and Ben-Neriah, 2000) . We determined whether LYG-202 inhibitory activity was due to inhibition of IB␣ phosphorylation HepG2 cells were transiently transfected with a NF-B luciferase reporter gene. After transfection, cells were pretreated with the indicated concentrations of LYG-202 for 6 h and then were incubated with 50 ng/ml TNF-␣ for an additional 18 h. Cell supernatants were collected and assayed for luciferase activity as described. C, LYG-202 inhibited the binding of NF-B to the COX-2 and MMP-9 promoters. HepG2 cells were pretreated with 2 M LYG-202 for 6 h and treated with 50 ng/ml TNF-␣ for the indicated times. The proteins were cross-linked with DNA by formaldehyde and then subjected to CHIP assay using an anti-p65 antibody with the COX-2 and MMP-9 primers. Values are means Ϯ S.D. for at least three independent experiments performed in triplicate ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01, compared with HepG2 cells treated with TNF-␣). GFP, green fluorescent protein.
and degradation. Western blot analysis indicated that TNF-␣ induced the phosphorylation of IB␣ within 15 min, whereas LYG-202 at 2 M blocked its phosphorylation (Fig. 4C , top row) and suppressed its degradation induced by TNF-␣ (Fig.  4C, middle row) .
The facts that TNF-␣-induced IB␣ phosphorylation requires IKK␤ (Hayden and Ghosh, 2004; Böcker et al., 2008; Schmid and Birbach, 2008) and is inhibited by LYG-202 prompted us to determine the effect of LYG-202 on IKK␤ activation. Results from the IKK␤ kinase assay showed that LYG-202 obviously suppressed IKK␤ activity in a dose-dependent manner (Fig. 4D ). These results demonstrate that LYG-202 inhibited TNF-␣-induced IB␣ phosphorylation and degradation and IKK␤ activity. Docking Analysis. After docking LYG-202 to each structure of the PDB, we ranked 11 target proteins that could activate IKK␤ activity according to the GOLD fitness score (Table 1) . Among these proteins, the crystal structure of human CK2 holoenzyme (PDB code 1ZOG) was the highestranked human protein with a fitness score of 47.8621, compared with the similar score of 48.2899 for the potent CK2 inhibitor CX-4945 (Pierre et al., 2011; Siddiqui-Jain et al., 2010) . The results demonstrated that CX-4945 could enhance TNF-␣-induced apoptosis (Supplemental Fig. 1B ) and inhibit NF-B activation (Supplemental Fig. 1C ). These effects of CX-4945 are similar to the corresponding characteristic effects of LYG-202, implying that CK2 may be a promising target of LYG-202 in blocking NF-B signaling activation.
Previous studies showed that the binding site was defined by analyzing the protein-ligand interactions of all 23 CK2 cocrystal structures that were deposited in PDB. All the ligands in the complex structures showed hydrophobic interactions with Val53, Val66, and Ile174, which play a crucial role in CK2 inhibition. In addition, Arg47, Lys68, Phe113, Val116, Asn118, Met163, and Asp175 are also very important in the binding interactions of CK2 and its ligands. A docking study showed that LYG-202 formed two hydrogen bonds with Asp175 and Asn118, the two key residues located in the polar region and hinge region, respectively, which were essential for CK2 activity. In addition, LYG-202 showed a favorable hydrophobic interaction with ARG43 in the binding pocket of CK2 (Fig. 5A) . The results indicated that LYG-202 could be considered to be a novel CK2 inhibitor that should be confirmed in the further biological tests.
Effect of LYG-202 on TNF-␣-Induced CK2 Activity. Protein kinase CK2 is a Ser/Thr kinase involved in various steps of the TNF-␣-induced NF-B activation process. We investigated whether LYG-202 directly inhibits TNF-␣-induced CK2 activity. Results from the CK2 kinase assay demonstrated that TNF-␣ induced the activation of CK2, and LYG-202 suppressed TNF-␣-mediated CK2 activity compared with CX-4945 (Fig. 5B) . Neither TNF-␣ nor LYG-202 affected the expression of CK2 protein subunits (Fig. 5C) .
Transfection of Protein Kinase CK2 Reverses the Effect of LYG-202. It was reported that CK2 could modulate IKK␤-mediated phosphorylation IB (Yu et al., 2006) . Molec- Cytoplasmic extracts (CE) and nuclear extracts (NE) were prepared, fractionated on SDS-polyacrylamide gel electrophoresis, and electrotransferred to nitrocellulose membrane. Western blot analysis was performed using the antibodies indicated. B, immunofluorescence analysis of p65 localization. Cells were incubated with 2 M LYG-202 for 6 h and then treated with 50 ng/ml TNF-␣ for 30 min. Cells were subjected to immunocytochemical analysis. C, effect of LYG-202 on the phosphorylation and degradation of IB␣ by TNF-␣. Cells were preincubated with 2 M LYG-202 for 6 h and then were treated with 50 ng/ml TNF-␣ for 30 min. Cytoplasmic extracts were fractionated and then subjected to Western blot analysis using the anti-IB␣ and anti-p-IB␣ antibodies. D, LYG-202 inhibits exogenous IKK␤ activity. The results shown are representative of three independent experiments.
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at ASPET Journals on June 26, 2017 molpharm.aspetjournals.org ular docking analysis showed that LYG-202 had hydrogen bonds with Asp175 and Asn118, which were essential for CK2 activity (Sun et al., 2010) , in the binding pocket of CK2; moreover, it inhibited TNF-␣-induced CK2 activity but had no effect on its expression (Fig. 5, B and C) .
To explore the potential role of CK2 in NF-B suppression induced by LYG-202, we detected the expression of CK2 in L02, HepG2, and HCT116 cell lines and transiently transfected CK2␣ (the catalytic subunit) and CK2␤ (the regulatory subunit) into cells to determine whether the elevated CK2 activity affects the activity of LYG-202. The results in Fig. 6A show that the expression of CK2 in L02 and HepG2cells is lower than that in HCT116 cells with a known high CK2 protein level, suggesting that we can transfect the HepG2cells with CK2␣ /CK2␤ plasmids to increase CK2␣ activity.
As shown in Fig. 6B , transfection of either CK2␣ or CK2␤ subunits or both gives rise to the expected patterns with the anti-Myc antibody. A 75, 20, and 102% increase in CK2 activities from HepG2 cells that were transfected with CK2␣, CK2␤, and both was observed compared with the control (Fig.  6C) . Results in Fig. 6D shown that the IKK␤ kinase activity showed little change in cells transfected with CK2␤ alone, but transfection of CK2␣ or both led to 30 and 54% increases in IKK␤ kinase activities. These data provide evidence that both are required for NF-B activation. In the following experiment, both of them were transfected to activate NF-B.
We tested the effect of LYG-202 on NF-B-dependent gene transcription and TNF-␣-induced apoptosis in the absence or presence of CK2␣ and CK2␤. Data indicated that the cotransfection of these two subunits reversed, at least partially, the inhibitory effect of LYG-202 on TNF-␣-induced NF-B-dependent gene transcription (Fig. 6E) , consequently diminishing the effect of LYG-202 on TNF-␣-induced apoptosis (Fig. 6 , F and G). These results implied that CK2 was involved in LYG-202 suppression of TNF-␣-induced NF-B activation in HepG2 cells. The results in Supplemental Fig. 2A show that CK2 siRNA down-regulated the mRNA of CK2 by nearly 75% PI3K, phosphatidylinositol 3-kinase; TAK1, transforming growth factor ␤-activated kinase 1; MAP3K7, mitogen-activated protein kinase kinase kinase 7; TRAF2, TNFR-associated factor 2; PKC, protein kinase C; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1. compared with the scrambled control. The data in Supplemental Fig. 2 , B and C, indicated that transfection of CK2 siRNA in HepG2 cells exhibiting a significant decrease in CK2 kinase activity produced lower levels of IKK␤ kinase activity than in control cells.
Furthermore, transfection of CK2 siRNA mimics the effect of LYG-202 on NF-B activation (Supplemental Fig. 2D ) and TNF-␣-induced cell apoptosis (Supplemental Fig. 2, E and F The results were a decrease in tumor volume (Fig. 7A ) and an increased inhibitory effect ( Fig. 7B ; Table 2 ) with the combination of 500, 250 , and 125 mg/kg) and TNF-␣ compared with the effects of LYG-202 or TNF-␣ alone, suggesting that treatment with LYG-202 and TNF-␣ together had more potential than that of either one alone in a mouse hepatoma H 22 solid tumor model. As shown in Table 2 , the CDI forLYG-202-treated groups (125 mg/kg) was smaller than 0.75, whereas the CDI for groups treated with 500, and 250 mg/kg) combined with TNF-␣ were between 0.75 and 1, indicating that the combining LYG-202 (125 mg/kg) and TNF-␣ produces a significant synergistic effect.
To further discover whether LYG-202 potentiates cancer cell apoptosis induced by TNF-␣ in vivo, we stained the solid tumor sections with a TUNEL apoptosis staining kit. As shown in Fig.  7C , application of LYG-202 in the mouse tumor model significantly increased TNF-␣-induced apoptosis in a dose-dependent manner. Furthermore, expression levels of the NF-Bregulated antiapoptosis genes including Survivin, XIAP, Bcl-2, and Bcl-xL were significantly decreased (Fig. 7D) in vivo, and 
Discussion
TNF-␣ is being used as an anticancer agent for locoregional treatment (Mocellin et al., 2005; Balkwill, 2009) . However, its role in cancer therapy is debated because of its paradoxical activity: the caspase cascade for apoptosis induction and the NF-B signal for cell survival promotion (Mocellin et al., 2005; van Horssen et al., 2006; Sethi et al., 2008) . Thus, a good way to explore agents that enhance TNF-␣-induced apoptosis is by attenuation of NF-B activation. Molecular docking analysis and biological tests showed that LYG-202, a known synthesized flavonoid derivative, probably attenuated the NF-B signal via inhibition of CK2 activity and may serve as a candidate compound for combination with TNF-␣.
In this study, we tested whether LYG-202 could sensitize hepatomas to treatment with TNF-␣.
In human hepatoma HepG2 cells, which are reported to be resistant to TNF-␣ (Sugimoto et al., 1999) , TNF-␣ alone had little effect on inhibition of proliferation and induction of apoptosis. Intriguingly, we even noticed that the cell fragment percentage slightly decreased compared with that for the control group. However, combination of TNF-␣ with LYG-202 significantly enhanced its antiproliferation and proapoptosis activities (Fig. 1) . Previous studies showed that NF-B is the major survival factor in preventing TNF-␣-induced apoptosis, and inhibition of this transcription factor may improve the efficacy of apoptosis-inducing cancer therapies (Orlowski and Baldwin, 2002; Mocellin et al., 2005; van Horssen et al., 2006; Pilati et al., 2008; Balkwill, 2009 ). Our results indicated that the protein expression of NF-B target genes including Survivin, XIAP, Bcl-2/Bcl-xL, c-Myc, COX-2, and cyclin D1 obviously decreased in the presence of LYG-202 (Fig. 2B) , and further findings demonstrated that LYG-202 suppressed NF-B transcription activity by disturbing the bond to its response elements (Fig. 3) . We also found that LYG-202 inhibited TNF-␣-induced phosphorylation and degradation of IB␣ (Fig. 4C) , a critical step for NF-B translocation into the nucleus (Zandi et al., 1997) , by attenuating IKK␤ activity (Fig. 4D ). All these observations suggested that LYG-202 enhanced TNF-␣-induced apoptosis by weakening NF-B activation.
CK2 is a highly conserved and ubiquitous serine/threonine kinase with a wide range of substrates involved in carcinogenesis and tumor progression (Litchfield, 2003; Yu et al., 2006) . In addition, CK2 has been found to show increased protein expression levels and nuclear localization in cancer cells compared with those in their normal counterparts. These findings promote CK2 as an unfavorable prognostic marker in several cancers and consequently as a relevant therapeutic target (Prudent et al., 2010; Sun et al., 2010; Trembley et al., 2010) . Recent studies report that CK2 contributes to aberrant NF-B activation though enhancement of IKK␤ activity for the phosphorylation of the Ser32/Ser36 NH 2 terminus of IB␣, a novel and distinct function from that of CK2 as a known COOH-terminal IKK␤ (Yu et al., 2006; Brown et al., 2010) . Inverse docking indicated that CK2 may be a potent target of LYG-202 in blocking of NF-B activation. Molecular docking analysis showed that LYG-202 formed hydrogen bonds with Asn118 and Asp175, the key residues located in the hinge region and polar region, respectively, in the active site of CK2, indicating that LYG-202 could bind stably with CK2 (Fig. 5A) . These results indicated that LYG-202 could be a potent and selective CK2 inhibitor and probably attenuate the CK2-mediated NF-B signal. Here, we found that LYG-202 inhibited CK2 activity but had no effect on its protein level (Fig. 5, B and C) , and overexpression of CK2 partially reversed the LYG-202 inhibitory effect on the TNF-␣-induced DNA-binding activity of NF-B in HepG2 cells (Fig. 6E) . Moreover, the apoptotic cell percentage of HepG2 treated with TNF-␣ and LYG-202 was reduced in the presence of CK2␣ and CK2␤ subunits, which show continuously active CK2 activity (Fig. 6, F and G) .
However, our studies showed that LYG-202 had little effect on NF-B activation and apoptosis when CK2 expression was almost completely inhibited by transfection with CK2 siRNA (Supplemental Fig. 2A ). The transfection of CK2 siRNA inhibited TNF-␣-induced DNA-binding activity of NF-B (Supplemental Fig. 2D ), induced HepG2 cell apoptosis, and mimicked the apoptotic potential of LYG-202 combined with TNF-␣ (Supplemental Fig. 2, E and F) . This evidence sug- 
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gests that CK2 played a crucial role in signal transduction that promotes HepG2cell growth and survival and may serve as a target of LYG-202 for the promotional effect on TNF-␣-induced apoptosis. Apigenin and other common flavonoids, which have been reported to be selective CK2 kinase inhibitors, suppress proliferation in a wide variety of solid tumors and hematological cancers (Davies et al., 2000; Zhao et al., 2011) and show significant inhibitory effects on CK2 activity and NF-B activation (Farah et al., 2003) . However, the possibility that LYG-202 could be a potent CK2 kinase inhibitor requires further assessment. Increased tumor vessel permeability is currently believed to be critical for TNF-␣ antitumor activity. TNF-␣ improves the pharmacokinetic profile of coadministered drugs by increasing the permeability of tumor vessels and lowering interstitial pressure within the diseased tissue (Lejeune, 2002) , which in turn augments the drug concentration within the tumor microenvironment van der Veen et al., 2000) . We found that LYG-202 exerted antiangiogenic activity both in vitro and in vivo (Chen et al., 2010b) , which could be another explanation for the synergy between LYG-202 and TNF-␣. Whether the effective contribution of TNF-␣ known to target tumor vasculature could promote the proapoptotic activity of LYG-202 needs to be investigated to fully realize its clinical potential.
Reactive oxygen species (ROS) generation in mitochondria is believed to play a key role in TNF-␣-induced apoptosis (SchulzeOsthoff et al., 1992; Goossens et al., 1995) . Previous studies have reported that LYG-202 induced HepG2 cell apoptosis through accumulation of ROS and its downstream signaling pathway (Chen et al., 2010a) . Thus, the role of generation of ROS in HepG2 cell death induced by TNF-␣ combined with LYG-202 is worth further investigation.
A number of studies have shown that levels of TNF-␣ are elevated in the plasma of patients with alcoholic hepatitis (Bird et al., 1990; Miró et al., 1999) . We found that LYG-202 with the combination treatment of TNF-␣ effectively suppressed H 22 murine solid tumor growth, induced tumor apoptosis, and down-regulated anti-apoptosis genes in xenograft mouse models (Fig. 7) . These results suggested that LYG-202 could be an effective agent in the treatment of patients with liver cancer with a high level of TNF-␣ secretion. However, whether the combination effect of LYG-202 with TNF-␣ in vivo occurs mainly via inhibition of CK2 activity should be further investigated, probably using a CK2␣ knockout mouse model.
In this study, we demonstrated that LYG-202 enhanced TNF-␣-induced apoptosis via attenuation of CK2 activity, which leads to the abrogation of NF-B activation in vitro and in vivo (Fig. 8) . These results extended our understanding of the molecular mechanisms underlying the improvement in TNF-␣ antitumor activities by LYG-202. 
